However, in the initial report describing variants in RNU7-1 as a cause of AGS, patient fibroblasts demonstrated a reduction in IFIT1 expression upon treatment with ruxolitinib (Uggenti et al. 2020), indicating the potential for treating such patients with JAK inhibitors. The gene discussed is RNU7-1; the disease is Aicardi-Goutieres syndrome.